Germany’s Standing Commission on Vaccination (STIKO) also recommends that people under 60 who have already received one shot of AstraZeneca should get a second dose of another vaccine.
The EMA came to the conclusion on Wednesday that the unusual blood clots suffered by numerous people around Europe should be considered as rare side effects of AstraZeneca’s Covid-19 vaccine, but that overall the benefits of the jab outweigh the risk.
They advised that the vaccine – developed with Oxford University – should continue to be used for all age groups but that people should be told of the possible rare side effects.
However, Germany’s vaccine committee recommended last week that the jab not be used in under 60s due to a small number of people developing a rare and potentially fatal condition called cerebral sinus venous thrombosis (CSVT) – a type of blood clot in the brain – after getting the AstraZeneca vaccine.
(article continues below)
See also on The Local:
The German government swiftly ordered that the use of AstraZeneca be stopped in people under the age of 60, but said that individuals can still decide to take the vaccine only after a consultation with the doctor carrying out the jab.
German infectious disease immunologist Christian Bogdan, a member of STIKO, told an online science briefing on Wednesday that the EMA’s decision was justified, but what STIKO decided “can certainly be justified in the same way”.
During the briefing organised by the Science Media Center, health experts said more research was needed to discover what may predispose people to clots with low blood platelet counts.
In Germany, there have been 31 suspected cases of CVST – 19 accompanied by a drop in blood platelets – with nine deaths, according to the Paul-Ehrlich Institute.
These cases were spread across 2.8 million AstraZeneca vaccine doses injected.
STIKO said the occurrence of CVST was therefore found in one to two out of 100 000 vaccinated younger women in Germany. There have also been a few cases in men in Germany – but 2.5 times more women nationwide have been vaccinated with an AstraZeneca dose so far.
You can read in-depth articles about the decision here:
- Why has Germany restricted the use of AstraZeneca in under 60s?
- Germany ‘cannot ignore AstraZeneca findings, says Merkel
Bogdan said, however, that the EMA decision would be discussed at the next committee meeting.
The German government has followed STIKO’s recommendations throughout the vaccine rollout.
What happens to people under 60 who have received one AstraZeneca dose in Germany?
The German committee recommended at the end of last week that people under 60 who had received one AstraZeneca shot should get a second dose of another vaccine.
They recommend administering an mRNA vaccine as the second dose. In Germany, the mRNA vaccines from BioNTech/Pfizer and Moderna are both approved.
Health Minister Jens Spahn has been discussing this topic with state health ministers and will soon release more information.
The chairman of STIKO, Thomas Mertens, told the Rheinische Post on Thursday that “protection against Covid-19 decreases after a certain time with a single AstraZeneca shot”.
He said a second dose from another vaccine could lead to an even higher protective effect from the disease.
However, high profile German virologist Hendrik Streeck said he was surprised at the committee’s recommendation to offer people in Germany a second dose with BioNTech or Moderna after AstraZeneca because of a lack of research.
“The clinical studies have not yet been carried out. I think it is necessary to stick to the rules and wait to see if the studies are successful,” he told the newspaper Fuldaer Zeitung.
But he said it was an “understandable” decision to restrict the use of AstraZeneca in people under 60 – even if the vaccine itself was effective and safe.